Developing a new method for cancer treatment using immune cells
Next Generation Autologous TIL Cancer Therapy: Development of GMP manufacturing process
This study is testing a new way to make a cancer treatment that uses special immune cells to better fight solid tumors, and it's designed for patients who are looking for more effective options in their cancer care.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Trampoline Pharma, INC. NIH-funded |
| Lab location | 1 site (Aurora, United States) |
| Project ID | NIH-10685604 on NIH RePORTER |
What this research studies
This research focuses on creating a manufacturing process for a new type of cancer therapy that uses tumor-infiltrating lymphocytes (TILs) to target solid tumors. The approach aims to enhance the effectiveness of TIL therapies by improving T cell activation and persistence in the tumor environment. By utilizing a novel platform that activates specific signaling pathways in T cells, the research seeks to overcome current limitations in TIL therapies, such as low tumor response rates and weak T cell activity. Patients may be involved in clinical trials to evaluate the safety and effectiveness of this innovative treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced solid tumors, particularly those who have not responded well to existing therapies.
Not a fit: Patients with early-stage cancers or those whose tumors are not solid may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve survival rates for patients with solid tumors.
How similar studies have performed: Previous studies have shown promising results with TIL therapies, indicating potential for success with this novel approach.
Where this research is happening
Aurora, United States
- Trampoline Pharma, INC. — Aurora, United States (Active)
Researchers
- Principal investigator: Duke, Richard C — Trampoline Pharma, INC.
- Study coordinator: Duke, Richard C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.